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Conventional and biologic disease-modifying antirheumatic drugs have revolutionized the medical therapy of inﬂammatory
arthritis. However, it remains unclear as to what can be done to treat immune-mediated chronic inﬂammation after patients
become refractory to these therapies or develop serious side-eﬀects and/or infections forcing drug withdrawal. Because of these
concerns it is imperative that novel targets be continuously identiﬁed and experimental strategies designed to test potential
arthritis interventions in vitro, but more importantly, in well-validated animal models of inﬂammatory arthritis. Over the past
few years, sphingosine-1-phosphate, interleukin-7 receptor, spleen tyrosine kinase, extracellular signal-regulated kinase, mitogen-
activated protein kinase 5/p38 kinase regulated/activated protein kinase, micro-RNAs, tumor necrosis factor-related apoptosis
inducing ligand and the polyubiquitin-proteasome pathway were identiﬁed as promising novel targets for potential antiarthritis
drug development. Indeed several experimental compounds alter the biological activity of these targets and have shown clinical
eﬃcacy in animal models of arthritis. A few of them have even entered the ﬁrst phase of human clinical trials.
Copyright © 2009 Charles J. Malemud.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The therapy of various types of inﬂammatory arthri-
tis, including, adult rheumatoid arthritis (RA), juvenile
idio-pathic arthritis (JIA), psoriatic arthritis and anky-
losing spondyloarthopathy that were previously treated
with glucocorticoids, nonsteroidal antiinﬂammatory drugs,
gold and bed rest was revolutionized by the introduc-
tion of the conventional disease-modifying antirheumatic
drugs (DMARDs), hydroxychloroquine, sulfasalazine, le-
ﬂunomide, azathioprine, cyclosporine, minocycline and
methotrexate monotherapy or several combined conven-
tional and biologic DMARD therapies into the standard
of medical care [1–3]. The advent of the use of biologic
DMARDs, including the 5 forms of anti-TNF-α-receptor
blocking molecules, inﬂiximab, adalimumab, certolizumab
pegol, golimumab and etanercept [4–7], interleukin-1-
receptor antagonist (IRAP) [8, 9], results from recent
clinical trials with canakinumab, a fully human monoclonal
antibody that neutralizes the bioactivity of human IL-1β
[10], abatacept, a selective modulator and inhibitor of the
T-cell costimulatory molecule CTLA-4 [11–13] and the
monoclonal antibody, rituximab which deletes a subset
of immature and/or memory B-cells expressing the CD20
cell surface protein marker [14–16] has added to the
armamentarium of useful drugs to treat patients with
inﬂammatory arthritis. Additionally, the positive results
obtained from recent clinical trials in adult RA and JIA
patients indicated that additional novel agents such as the
anti-IL-6 receptor (IL-6R) blocking monoclonal antibody,
tocilizumab [17, 18], which has been approved for use in
Europe, India and Japan are likely to be approved in the
United States by the Federal Drug Administration in the
not too distant future. Nevertheless, there is compelling
evidence which indicates that patients with inﬂammatory
forms of arthritis can become unresponsive or refractory
to the currently available conventional DMARDs and/or
biologic DMARDs and develop serious side-eﬀects including
neutropenia, auto-antibodies, antiidiotypic antibodies (even
to some anti-TNF-α or anti-IL-6R monoclonal antibodies
c h a r a c t e r i z e da sf u l l yh u m a n i z e d )a sw e l la sr e a c t i v a t i o n
and/or the onset of new bacterial infections especially at2 Mediators of Inﬂammation
higher than recommended anti-TNF-α doses which may
require withdrawing the drug [4, 19–24]. These ﬁndings
in the biologic DMARD postmarketing surveillance period
likely necessitates that new antirheumatic targets be con-
tinuously identiﬁed. Experimental agents that interact with
these newly discovered targets must be thoroughly examined
for their eﬀects in vitro as well as in animal models of
inﬂammatory arthritis prior to any consideration of their
use in assessments of safety, eﬃcacy and disease-modifying
activity in patients with inﬂammatory arthritis.
A previously published compilation of review arti-
cles highlighted the recent advances in the identiﬁcation
of novel targets and cellular processes in RA, which
included non-IL-1, non-TNF-α and non-IL-6 proinﬂamma-
tory cytokines, chemokines, adhesion molecules, vascular
endothelial growth factor and insulin-like growth factor-
1, matrix metalloproteinases (MMPs), complement and
pro- and antiapoptosis molecules [25] as well as the Janus
kinase/Signal Transducers and Activators of Transcription
(JAK/STAT) pathway whereby the Jak3 inhibitor, CP690550
is the ﬁrst small molecule inhibitor (SMI) to reach phase III
clinical trials status [26], Mitogen-Activated Protein Kinase
(MAPK) pathway [27, 28], and the IL-6/IL-6 receptor/gp130
complex [29, 30], all of which are applicable to additional
basic and clinical studies wherein their future use in the
medical intervention of adult and childhood RA and other
inﬂammatory arthopathies may be further assessed.
This review will critically evaluate the extent to which
several molecules, including, sphingosine-1-phosphate
(S1P), IL-7-receptor (IL-7R), spleen tyrosine kinase (SyK),
MEK/ERK 1/2, Mitogen-activated protein kinase 5/p38
kinase regulated/activated protein kinase (MK5/PRAK),
microRNA (miRNA), tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and inhibitors of prote-
asome activity, appear to be promising novel experimental
targets for future drug development for the treatment of
inﬂammatory arthritis.
2. Sphingosine-1-Phosphate (S1P)
Sphingosine-1-phosphate (S1P) is a signaling sphingolipid
and a bioactive lipid mediator [31]. Although once only
recognizedasregulatorofangiogenesis,vascularhomeostasis
and permeability [31], the most recent evidence indicated
that S1P was a critical regulator of T-cell and B-cell traﬃck-
ing [32] and macrophage function [33]. Thus, the binding
of S1P to its receptors, S1PR1/S1PR2 [34], triggers and is
required for stimulating the movement of immune cells
from the thymus and lymph nodes into lymphatic vessels
from where they can travel through peripheral circulation to
synovial joints. Additionally, it was shown that the secreted
form of S1P also regulated cell survival and apoptosis by its
capacity to bind to and activate 5 speciﬁc G protein-coupled
receptors, S1P1-S1P15 [35].
S1P is produced by the activation (i.e., phosphorylation)
ofsphingosine(Sph)viaits2isoformsofsphingosinekinase-
1/2(SphK-1/2)resultingintheproductionoftheprosurvival
S1P molecule with decreasing levels of the proapoptotic
Sph molecule [35]. Thus, inhibiting the formation of S1P
either by targeting SphK, or by inhibiting the binding of
S1P to S1PR1/S1PR2 is likely to result in a reduced egress
of activated T-cell and B-cell from lymphoid tissues and
presumably fewer activated lymphocytes making their way
into the synovium. These strategies may even be useful
for also targeting apoptosis resistance which is a common
hallmark of RA synovium [36, 37].
What is the current evidence that altering the activity
of S1P would provide signiﬁcant and beneﬁcial eﬀects by
restricting some of the pathophysiologic events that con-
tribute to inﬂammatory arthritis? Firstly, aberrant synovial
cell proliferation is a signature event in RA [38]. Thus, it is
likely that studying cell lines with an abnormal capacity for
proliferation might be useful in dissecting out the role of S1P
in regulating DNA synthesis. In that regard, several murine
F9 embryonic carcinoma cell lines were produced with
varying expressional levels of the S1P-degrading enzyme,
S1P lyase (SPL) and/or SphK1 [39]. F9 cells overexpressing
SphK1 exhibited elevated DNA synthesis, whereasother S1P-
accumulating cells or SPL-null cells overexpressing SphK1
did not. These studies suggested that it was SPL, rather than
S1P, that regulated mitogenesis in this cell line. Furthermore,
genetic studies in mice expressing reduced levels of SPL
showed decreased circulating lymphocytes as a result of
alterationsinlymphocytetraﬃckingandstudiesoflymphoid
tissues following oral administration of 2-acetyl-4(5)-(1(R),
2(S), 3(R), 4-tetrahydroxybutyl)-imidazole, an experimental
inhibitor of SPL, showed a clear relationship between
reduced SPL activity, elevated S1P levels, and lower levels of
circulating lymphocytes [40], thus supporting the targeting
of S1P signaling as a potentially important antiinﬂammatory
pathway [41].
Of note, on August 27, 2009, Lexicon Pharmaceuticals
announcedthatanorally-administeredSMIofSPL,2-acetyl-
4(5)-(1(R), 2(S), 3(R), 4-tetrahydroxybutyl)-imidazole (i.e.,
LX2931), was being assessed in a Phase 2 multicentered
randomized, double-blinded placebo-controlled clinical trial
in the US and Eastern Europe on subjects with active RA
who were also receiving methotrexate [42]. The ACR20
response to LX2931 will be the primary study endpoint. In
the Phase 1a clinical trial conducted on normal volunteers, a
dose-dependent decrease in absolute lymphocyte count and
a maximal eﬀect correlating with the plateau in systemic
exposure at doses of 100 to 125mg of LX2931 was observed.
An episode of acute abdominal pain which resolved within
24 hours was observed in 2 of 24 subjects in this single
ascending-dose trial when subjects received doses of LX2931
above 175mg, a dose which potentially represented (accord-
ing to the manufacturer) a dose-limiting tolerability level.
Another line of evidence suggesting a role for S1P in
R As t e m sf r o ms t u d i e si nw h i c hT N F - α induction of COX-2
activity and PGE2 synthesis was studied in L929 ﬁbroblasts
[43]. Of note, S1P induced COX-2 and PGE2 in a dose-
dependent (100–300nM) manner. Small interfering RNAs
(siRNA) directed against SphK decreased SphK1 protein
and inhibited TNF-α-induced SphK activity. Interestingly,
siRNA directed against S1P or S1P phosphatase (SPP) also
enhanced COX-2 and PGE2 production, whereas siRNAMediators of Inﬂammation 3
directed against SphK1 inhibited the eﬀects of exogenous
Sph and ceramide on the induction of PGE2 indicating that
it was the intracellular metabolism of S1P that regulated
COX-2 and PGE2 induction. However, the extent to which
experimental strategies of this kind will produce similar
results when employed in cultures of normal synovial
ﬁbroblasts or RA ﬁbroblast-like synoviocytes (RA-FLS) has
not been established. It is also noteworthy that silencing of
SPP2 by siRNA also led to a marked reduction in TNF-α-
induced IL-1β and a partial reduction in IL-8 in endothelial
cells [44] suggesting that the targeting of SPP2 may also
eﬀectively limit the proinﬂammatory role of S1P.
3. IL-7Receptor
Expression of the IL-7 receptor (IL-7R) gene (also known
as CD127) plays a central role in thymocyte development
[45], T-cell survival, B-cell maturation, T-cell-dendritic cell
(DC) interactions [46, 47], as an inducer of lymphoid tissue
development [48] as well as being useful for identifying T-
regulatory (Treg) cells producing the FoxP3 phenotype [49].
To function normally, the IL-7R requires the presence of the
IL-2 receptor gamma chain (IL-2Rγ) which is the common
γ-chain (Figure 1) that is shared by the receptors of various
cytokines including IL-2, -4, -7-,-9 and -15, -21. In that
context, IL-2Rγ h a sb e e nr e p o r t e dt ob ec r i t i c a lf o rV ( D ) J
recombination during lymphocyte development [50]. IL-7R
was also found to important in regulating the accessibility
of the T-cell receptor (TCR) γ-locus (TCR-γ)b yS T A T 5a n d
histone acetylase [51]. Thus, overexpression of IL-7Rα is
likely to be highly relevant to the pathogenesis and even to
the progression of inﬂammatory arthritis.
For example, it was shown that murine T-cell and B-
cell development was dependent on IL-7Rα, in that forced
expression of the antiapoptosis gene Bcl-2 in murine T-
cells from IL-7Rα deﬁcient mice resulted in restoration of
thymic positive selection and normal T-cell numbers and
function [52]. Interestingly, a deﬁciency in the proapoptosis
gene, Bax, also partially corrected IL-7Rα deﬁciency and the
BH3-domain containing apoptosis proteins Bad and Bim
were implicated as contributing to the apoptosis pathway
suppressed by IL-7/IL-7R [53]. Additionally, in contrast to
IL-7R null mice, Flt3 null mice crossed with IL-7R null
mice failed to produce mature B-cells or for that matter,
B-cell precursors during fetal development [54]. Taken
together, these results indicated that IL-7Rα was required
for normal T-cell and B-cell development. Thus, defective or
overexpressed IL-7/IL-7Rα signaling could be critical in the
regulation of other receptor-mediated events that regulate
apoptosisaswellasimmune-mediatedeventsthatcontribute
to inﬂammatory arthritis.
Several criteria needed to be met in order for IL-7R to
be further considered as a promising target for experimental
intervention in inﬂammatory arthritis. First and foremost
would be evidence for elevated levels of IL-7 in the synovial
ﬂuid of joints with inﬂammatory arthritis. A recent review of
the literature by Churchman and Ponchel [55] indicated that
this indeed was the case. However, one of the ﬁrstindications
that IL-7 was likely to play a critical role in experimental
inﬂammatory arthritis also stemmed from the earlier studies
by Sawa et al. [56] who showed that mice homozygous
for the F759 mutation in the gp130/IL-6R subunit showed
elevated Stat3 activation and a rheumatoid-like arthritic
joint disease. Furthermore, the gp130 mutation resulted
in elevated levels of IL-7. In turn, conditional knockout
of Stat3 in nonlymphoid cells showed that the increased
levels of IL-7 in these mice were Stat3-dependent. Anti-IL-7
antibodynotonlyinhibitedCD4+ T-cellproliferation(which
was a requirement for the development of arthritis) but
anti-IL-7 antibody administration also ameliorated arthritis
severity. Thus, arthritis produced in these mice by the F759
mutation in gp130 required not only homeostatic CD4+ T-
cell expansion but upregulation of IL-7 gene expression in
nonhemopoietic cells as well.
Turning to studies in human RA, Kim et al. [57] showed
that elevated levels of IL-1β and TNF-α in RA synovial ﬂuid
typicallyincreasedstromalcellproductionofIL-7invitro.In
turn, IL-7 was also shown to upregulate production of TNF-
α in monocytes. Of note, IL-7 was shown to be an important
inducer of osteoclastogenic cytokines in T-cells by RANKL,
the latter a strong promoter of bone destruction in RA.
Most importantly, this event was apparently independent
of TNF-α [58], suggesting that anti-TNF-α therapies would
be unlikely to completely abrogate IL-7-mediated cellular
events in RA. However, van Roon et al. [59] showed in
vivo that TNF-αR blockade did block IL-7 production in
those RA patients that responded to anti-TNF-α therapy,
but high IL-7 levels persisted in anti-TNF-α nonresponders.
More recently, Hartgring et al. [60] also found signiﬁcantly
higher levels of IL7Rα in the synovial ﬂuid from RA and
undiﬀerentiated arthritis patients which strongly correlated
with elevated levels of IL-7 and increased numbers of the
CD3+ T-cell subset. Interestingly, a large number of B-cells
and macrophages also expressed IL-7Rα although this was
less signiﬁcant than was found for T-cells. Additionally, there
was a strong correlation between IL-7Rα-expressing T-cells
that also failed to express FoxP3 which showed marked
proliferation in vitro compared to IL-7Rα-expressing T-
cells that expressed FoxP3. Experimental exv i v ostudies
on monocytes collected from RA patients when treated
with recombinant human soluble IL-7Rα in vitro inhibited
IL-7-induced T-cell proliferation and interferon-γ (IFN-
γ) production, suggesting that IL-7Rα blockade might of
potential importance as an alternative strategy to TNF-α
blockade for limiting IL-7-induced RA immunopathology.
This point wasalso stressed by Vudattu et al.[61] fortreating
patients with autoimmune diseases associated with central
nervous system inﬂammation.
4. Spleen TyrosineKinase
Spleen tyrosine kinase (SyK) (Figure 2)a n dζ-chain associ-
ated protein-70 (ZAP-70) are nonreceptor kinases that are
primarily expressed in hemopoietic cells, including cells of
thespleen,mastcells,neutrophilsandmacrophages[62].Syk
and ZAP-70 are also involved in T-cell and B-cell receptor4 Mediators of Inﬂammation
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Figure 1: The IL-7/IL-7R Pathway. The IL-7R is composed of a γC and Rα polypeptide. The Rα component is unique to the IL-7R, whereas
γC is common to several cytokine-mediated pathways, including IL-2, IL-4, IL-9, IL-15 and IL-21. The binding of IL-7 to Rα results in
the dimerization of γC and Rα. JAK3 is associated with γC. After dimerization of γCw i t hR α, JAK3 can phosphorylate Rα and/or JAK1.
Activation of JAK3 results in phosphorylation of STAT5. Phosphorylation of STAT5 is required for STAT5 to act as a transcription factor
(reviewed in [26]).
signaling potentially making Syk and ZAP-70 enzyme targets
forthetreatmentofautoimmunediseases[63].Ofnote,since
Cbl ubiquitin ligase was previously shown to be a negative
regulator of Syk [64], various experimental attempts have
been made to limit SyK activation through targeting of the
polyubquitination-proteasome pathway [65, 66].
Because of its apparent critical role in regulating T-cell
and B-cell expansion and the proliferation of cells containing
the Fγ-activating receptor as well as mediating immunore-
ceptorsignalingininﬂammatorycellsandimmunecomplex-
mediated signal transduction, SyK must be considered a
promising target for designing interventional drugs for the
treatment of immune-mediated inﬂammatory arthritis. At
the experimental level, Pine et al. [68] showed that R788
a prodrug of the active novel SyK small molecule inhibitor
R406 suppressed the severity of arthritis, bone erosions,
pannus development and synovitis in murine collagen-
inducedarthritis(CIA).ThereducedexpressionofSyKinthe
R788-treated mice correlated with an amelioration of clin-
ical arthritis, a reduction in proinﬂammatory chemokines
and cytokines, including the CXCR2 ligand KC-GRO-α,
macrophage chemoattractant protein-1 (MCP-1), IL-1, and
IL-6, as well as inducing suppression of cartilage oligomeric
matrix protein release, the latter protein a sensitive in
vitro biomarker for articular cartilage extracellular matrix
degradation.
Because of the apparent successful preclinical response
to R788 in the well-validated CIA animal model of RA, a
Phase II clinical trial involving, fostamatinib (R406), was
conducted. Fostamatinib eﬀectively improved clinical RA
response rates within a 3 month treatment period with gas-
trointestinal side-eﬀects, principally diarrhea, and neutrope-
nia, which was related to the fostamatinib dose employed,
themostcommonlyreportedadverseevents[69].Inaddition
toimprovingclinicaloutcomesmeasurementsasdetermined
by the American College of Rheumatology (ACR) criteria as
early as 1 week after oral administration, R406 also reduced
the level of serum IL-6 and MMP-3 (stromelysin-1) in the
groups receiving 100mg and 150mg of R406 twice daily
[70]. However, it remains to be determined as to the extent
that R406 can be continuously employed in the treatment
of chronic RA, the extent to which reduced levels of SyKMediators of Inﬂammation 5
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Figure 2: The Role of Syk in Antigen-Mediated Activation of
the B-cell Receptor. The B-cell receptor (BCR) is composed of
a ligand binding moiety that interacts with antigen (Ag) and a
signaling moiety in the form of the heterodimer, Ig-α/Ig-β complex,
(also known as CD79) which is held together by disulﬁde bridges.
Each component of the Ig-α/Ig-β heterodimer complex spans the
plasma membrane and also possesses a cytoplasmic tail component
containing the immunoreceptor tyrosine-based activation motif
(ITAM). In this example, the binding of Ag to BCR triggers
phosphorylation of Syk. Activation of Syk regulates phospholipase
Cγ (PLCγ) activity. PLCγ2 was recently shown to be required for
the formation, maintenance and survival of memory B cells within
germinal centers [67].
are maintained by administration of R406 and whether
R406 therapy will show a sustained improvement in arthritis
symptoms compared to that obtained with conventional or
biologic DMARDs.
5.MEK/ERK1/2
ERK1/2belongstotheSAP/MAPKfamilyofproteinkinases.
ERK 1/2 must be activated before it can act as a fully
activated protein kinase and as such the activation of an
MAPK such as ERK 1/2 is generally carried out by one of
at least 7 upstream MKK proteins [71]. Moreover, MKK
activity is also regulated by further upstream MKKK and
MKKKK activity that are either tyrosine or serine-binding
proteins which may also require low molecular weight
GTP-binding proteins for MKKK activation. Much of the
accumulated evidence has indicated that the MKK-MAPK
activated protein kinase complex is further organized by
additional scaﬀolding proteins that provide the structural
requirements for speciﬁc MKKK activation selectivity for the
action of GTPases, additional protein kinases and receptors
[72].
MEKisthekeyregulatoryproteinkinaseactivationinthe
Ras/Raf/MEK/ERK pathway (Figure 3). In that regard, MEK
is critical for the upregulation of several proinﬂammatory
cytokines, including, TNF-α,I L - 1 β and IL-6 [73]. Addition-
ally, in the context of inﬂammatory arthritis, recent studies
using the novel MEK SMI AZD6244 showed that AZD6244
inhibited osteoclastic diﬀerentiation, function and cytokine
production in dentine disc cultures [74]w h e r e a sap r e v i o u s
study showed that 2 MEK SMIs, U0126 and PD98059,
blocked osteoclast development from the RAW264.7 pre-
osteoclastic cell line [75]. These results suggested that MEK
blockade could be useful for attenuating proinﬂammatory
cytokine synthesis as well as for suppressing osteoclast-
mediated bone erosions in inﬂammatory arthritis. How-
ever, the “cross-talk” that is known to occur between the
JAK/STAT and MEK/ERK pathway [28, 76] likely also creates
an added layer of complexity for regulating osteoclast func-
tion in inﬂammatory arthritis since the JAK/STAT pathway
has also been considered as a suitable target pathway for
the suppression of inﬂammatory disorders [26]. In that
regard, Kwak et al. [77] showed that AG-490, an inhibitor
of Jak2/Jak3 activity, actually induced osteoclast survival
by activating both the MEK/ERK and PI3K/PTEN/Akt cell
survival pathway. Thus, it is worthwhile considering the
possibility that inhibition of osteoclast function using other
novel strategies that target RANKL [78, 79] may also be
required in this context.
Compelling evidence arising from malignant transfor-
mation studies in which MEK SMIs were employed in vitro
has also implicated Raf/MEK/ERK [80]a sac o m p o n e n t
of a “cross-talking” network with the PI3K/PTEN/Akt cell
survival pathway [81]. The results of these studies suggested,
however, that inhibition of MEK/ERK may have only limited
therapeutic beneﬁt for dampening synoviocyte proliferation
and hyperplasia that is a hallmark of rheumatoid synovial
pannus. Nevertheless, Thiel et al. [82] showed that the
selective MEK SMI, PD184352 suppressed murine CIA paw
edema and clinical arthritis scores while also reducing IL-
1α-induced activated ERK levels in human synovial ﬁbrob-
lasts as well as inhibiting proteoglycan loss from articular
cartilage slices in vitro. Another experimental ERK inhibitor,
FR180204, also suppressed murine CIA arthritis in which
amelioration of clinical arthritis by FR180204 may also
involve reduced antigen-speciﬁc activation of murine T-
cells [83]. However, in the ﬁrst clinical trial of its kind
in RA patients to employ a speciﬁc MEK SMI, ARRY-162,
used in combination with a stable dose of methotrexate,
none of the ARRY-162 treatment groups demonstrated
a signiﬁcant ACR20 response compared to placebo after
12 wks [84]. This result conﬁrmed a previous European
clinical trial with ARRY-162 which also failed to achieve
a statistically signiﬁcant outcome in clinical improvement.
Thus, it remains to be determined if the “positive” results
obtained in experimental inﬂammatory arthritis employing
speciﬁc MEK/ERK SMIs can ever be translated into future
use for the therapy of human RA.6 Mediators of Inﬂammation
Growth factors,
mitogens,
GPCR
A-Raf, B-Raf, c-Raf MEK 1/2 ERK 1/2
Growth,
diﬀerentiation,
develpment
Figure 3: Activation of MEK 1/2 and ERK 1/2 by MAP3K. The phosphorylation (i.e., activation) of A-Raf, B-Raf or c-RAF, by MAPKKK
(i.e., MAP3K) results in MAP2K-mediated phosphorylation of MEK 1/2 and downstream activation of ERK 1/2 (reviewed in [27]).
6.Mitogen-ActivatedProteinKinase 5/p38
KinaseRegulated/ActivatedProteinKinase
Mitogen-activated protein kinase 5 (MK5) also known
as p38 kinase regulated/activated protein kinase (PRAK)
is a 471 amino acid protein with a 20%-30% sequence
identity to the cyclic AMP responsive element binding
protein, CREB-phosphorylating MAPK-regulated protein
kinase RSK-1, -2, -3 [88–90]. MK5/PRAK was found to
be expressed in most human tissues and activated by cell-
stressors and proinﬂammatory cytokines in vitro. In turn,
PRAK activity was regulated by p38α and p38β activity.
Once activated, MK5/PRAK was reported to directly phos-
phorylate heat shock protein 27 (Hsp27) [91, 92], the latter
having been implicated in several physiologically relevant
immune-mediated inﬂammatory responses such as CD8+
lymphocyte subset expansion and apoptosis resistance [93]
as well as in the activation of the Toll-like receptor-4 in
monocyte-derived RA DCs [94]. Additionally, the conven-
tional DMARD, methotrexate, was shown to enhance PGD2-
stimulated Hsp27-induction in MC3T3-E1 osteoblasts at a
point downstream of MAPKs [93]. MK5/PRAK was also
shown to activate atypical ERK 3/4 [95], but the signiﬁcance
of this pathway in inﬂammatory arthritis remains unclear.
However, the MK5/PRAK promoters of human, mouse and
rat all contain a cyclic AMP (cAMP) responsive element
that binds to CREB in vitro [96], indicating that molecules
involved in inﬂammatory arthritis that also activate cAMP-
dependentproteinkinaseA(e.g.,PGE2),mayalsoupregulate
MK5/PRAK transcription.
It was suggested that novel upstream p38α-speciﬁc SMIs,
such as SD-282 (indole-5-carboxamide) could potentially be
useful inhibitors of p38α-driven inﬂammation [97]. Thus,
p38α inhibition by SD-282 may also aﬀect downstream
MK5/PRAK-driven p38 kinase-regulated pathways as well
[98]. Additionally, Sun et al. [99] reported that PRAK
activated the tumor suppressor p53 by direct phospho-
rylation. Although it has not been directly determined,
PRAK may therefore also be also involved in p53-mediated
transactivation activity of inﬂammatory response genes,
such as PGE2 [100], as well as playing a role in the
regulation of murine CIA responses [101]. In the latter,
Type II collagen-stimulated T-cell activation and IFN-γ
production ex vivo was signiﬁcantly higher in p53 null
mice with CIA compared to their wild-type counterparts
[101].AnexperimentalinhibitorofMK5/PRAK,GLPG0259,
was reported to provide “excellent” protection against bone
erosion as well as reducing inﬂammation in an RA animal
model [102].
7. MicroRNAs
Micro- RNAs (miRs) are small noncoding RNA molecules
composed of double-stranded RNAs of 21–25 nucleotides
derived from endogenously expressed transcripts with char-
acteristic hairpin structures (Figure 4). miRs are known to
negatively regulate gene expression at the posttranscriptional
level [103, 104]. Lewis et al. [105] ﬁrst proposed that perhaps
as much as one-third of all mRNAs were targets for miR-
mediated regulation. Inthecontextof theputative epigenetic
role for miRs in regulating the inﬂammatory response in RA
[106],Taganovetal.[107]showedthatmiR-146a/b,miR-132
and miR-155 were endotoxin-responsive. Moreover, miR-
146a was also found to be an NF-κB-responsive gene with
miR146a/b predicted to interact with sequences of the 3 
untranslated region of TNF-associated factor-6 (TRAF6)
and IL-1 receptor-associated kinase-1 (IRAK-1) genes which
are 2 key adaptor molecules intimately involved in theMediators of Inﬂammation 7
Table 1: Some novel experimental therapies alter the severity of arthritis in animal models.
Target Drug Animal Model Results Reference
Spleen Tyrosine Kinase R788/R406 Murine CIA† ↓ Arthritis [68]
↓ Cytokines
MEK PD184352 Murine CIA
↓ Arthritis [82]
↓ Proteoglycan degradation
ERK FR180294 Murine CIA ↓ T cell activation [83]
miR-15a miR-15a Murine Autoantibody‡
↑ Apoptosis
[85] ↓ bcl-2
↑ caspase-3
TRAIL rhTRAIL∗ Rabbit IL-1β-transfected ﬁbroblasts∗∗ ↑ Apoptosis
[86] ↓ Lymphocyte inﬁltration
Proteasome Bortezomib Murine CIA
↓ Arthritis
[87] ↓ TNF-α,IL-1β, IL-6,iNOS, COX-2
↓ MMP-3
† Type II Collagen-Induced Arthritis
‡ FAM-atelocollagen + miR-15a
∗ Recombinant human TRAIL
∗∗ IL-1β-transfected human ﬁbroblasts engrafted into rabbit synovial joint.
regulation of the Toll-like receptor (TLR) and cytokine
receptor pathways. Thus, expression of the miR146a/b could
be expected to alter the functional regulation of these
signaling pathways. Another piece of the miR story with
speciﬁc relevance to inﬂammatory arthritis emerged when
O’Connell et al. [108] demonstrated that miR-155 was
the only miR to be upregulated in monocyte cultures
by either polyriboinosinic acid:polyribocytidylic acid [poly
(I:C)], a synthetic ligand that activates the TLR pathway, and
interferon-β(IFN-β).TLRligandsthatinducedmiR-155also
required myeloid diﬀerentiation factor 88 (MyD88) or the
TIR-domain-containing adapter-inducing IFN-β (TRIF)-
associated TLR3/TLR4 molecules. Furthermore, inhibition
of c-Jun-N-terminal kinase (JNK) blocked miR-155 induc-
tion induced by [poly (I:C)] or TNF-α.
These initial studies provided the impetus for con-
sidering miRs as potential novel experimental targets in
inﬂammatory arthritis. In that regard, Nakasa et al. [110]
showed that mature miR146a and primary miR146a/b
were highly expressed in RA synovial tissue where it was
principally found in CD68+ macrophages with a smaller
percentage of CD3+ T-cells and CD79a+ early progenitor
B-cells also producing miR146a/b. In vitro miR146a/b was
markedly upregulated in RA-SF by TNF-α and IL-1β,a n
indicatorthathighlevelsoftheseproinﬂammatorycytokines
found in RA synovial ﬂuid were likely to be responsible
for the elevated level of miR146a/b found in RA synovial
tissue. Stanczyk et al. [111] conﬁrmed the basic ﬁndings
of O’Connell et al. [108] and Nasaka et al. [110]a n d
further showed higher levels of miR-146a and miR-155
in RA synovial tissue compared to synovial tissue from
patients with osteoarthritis. Furthermore, Stanczyk et al.
[111] showed that forced expression of miR-155 repressed
the levels of MMP-3 (stromelysin-1) produced by RA-SF.
miR-155alsoreducedtheexpressionofMMP-1(collagenase-
1) and MMP-3 induced by TLR ligands, TNF-α,I L - 1 β,
[poly(I:C)]andbacteriallipoprotein.Morerecently,elevated
expression of miR-146a, miR-155, miR-132, miR-16, but
not miR-let-7a expression was found in RA synovium [112]
with elevated miR-146a levels also found in circulating RA
monocytes. Interestingly, TRAF6, and IRAK-1, two targets
of miR-146a [107] were produced at similar levels in RA
and control monocytes, despite the ﬁnding of increased
miR-146 expression by RA monocytes. This result suggested
that miR-146a produced by RA monocytes was apparently
nonfunctional. As such, defective miR-146a could contribute
to the dysregulation of TNF-α-signaling in RA since repres-
sion of TRAF6 and IRAK-1 in THP-1 cells resulted in an
86% reduction in TNF-α. Finally, Nagata et al. [85] showed
in an autoantibody-induced model of murine inﬂamma-
tory arthritis in DBA/1 mice that double-stranded miR-
15acoadministeredintra-articularlywithFAM-atelocollagen
complex resulted in elevated expression of miR-15a in
the arthritic mouse synovium compared to mice injected
with siRNA-atelocollagen complex representing the control
group. Interestingly, the antiapoptotic protein bcl-2 was
downregulated by miR-15a whereas caspase-3 was increased
by miR15-a in the mice with autoantibody-induced arthritis
compared to the control group. These results suggested
that experimental therapy with miR-15a was capable of
inducing caspase-3-dependent apoptosis in RA synovium by
suppressing bcl-2 expression.
8. Tumor Necrosis Factor-Related
Apoptosis-InducingLigandReceptors
The failure of apoptosis to rectify aberrant cellular pro-
liferation signals that activate synoviocytes, T- and B-
cells, macrophages and osteoclasts is a signature event in
various forms of inﬂammatory arthritis [36, 37]. Several
intracellular processes have been identiﬁed as being defective
in the regulation of apoptosis in inﬂammatory arthritis.8 Mediators of Inﬂammation
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Figure 4: The miR Pathway. Step 1 of the miR pathway involves the transcription of a 70–100 nucleotide (nt) pri-miR from an miR gene
which is then processed in the nucleus via Step 2 by the RNAse III enzyme, DROSHA to yield pre-miR. Following the transport of pre-miR
from the nucleus to the cytoplasm mediated by the nuclear export receptor protein, EXPORTIN 5 at Step 3, a second RNAse III enzyme,
DICER, digests pre-miR at Step 4 resulting in a 21–25 nt miR. At this juncture, miR has the capacity to bind to the RNA-Induced Silencing
Complex (RISC) and at Steps 5 and 6 aligns itself with an mRNA. The ﬁnal step (Step 7) is dependent on whatever complimentarity exists
between a miR and a target sequence in mRNA. Therefore, the degree of complimentarity between a miR and an mRNA results in either
translational repression or mRNA cleavage (reviewed in [109]).
These include, the prominence of the PI3K/PTEN/Akt cell
survival pathway [113, 114], upregulation of HSP70 gene
expression [115], suppressed Fas/CD95-mediated signaling
[116], activation of NF-κB[ 117, 118] by the proinﬂamma-
tory cytokines, IL-1β and TNF-α [119], by reactive oxygen
species and nitrogen reactive species [120]a sw e l la st h e
activity of antiapoptotic BH3-proteins of the bcl-2 family
[37, 121], all of which dampen the apoptosis signaling
cascade. Despite the potential that these cellular events could
be targeted for intervention in inﬂammatory arthritis, recent
attention has been mainly focused on the critical role of
tumor necrosis factor- (TNF-) related apoptosis-inducing
ligand (TRAIL) as a target for elevating the frequency of
apoptosis in immune-mediated inﬂammatorycellsprimarily
because agonist TRAIL-receptor-speciﬁc antibodies have
shown encouraging results in promoting apoptosis in cancer
cells in some clinical trials [122].
Morel et al. [123] ﬁrst showed that TRAIL induced RA-
SF proliferation through activation of MAPK and PI3K/Akt
since RA-SF proliferation could be inhibited by the ERK
1/2 SMI, PD98059, the p38 kinase SMI, SB203580 and the
PI3K/Akt SMI, LY294002, respectively. TRAIL also inducedMediators of Inﬂammation 9
apoptosis in about one-third of the cells but in the cells that
survived, TRAIL promoted RA-SF proliferation. Of note,
TRAIL-mediated RA-SF proliferation could be blocked by
neutralizing anti-TRAIL antibody. Trichostatin A (TSA), a
Streptomyces metabolite which speciﬁcally inhibits mam-
malian histone deacetylases was shown to sensitize RA-SF
to TRAIL-induced apoptosis, whereas TRAIL or TSA alone
were unable to induce RA-SF apoptosis [124]. The results of
this study suggested that the initial small apoptotic response
of RA-SF to TRAIL reported by Morel et al. [123]m a yh a v e
been due to the presence of inactive sites in the cascade of
TRAIL-signaling that were uncovered by administering TSA
which resulted in an increase in the frequency of apoptotic
cells.
Monocyte production of IFN-γ also appeared to be
critical in the dampening of TRAIL-mediated apoptosis in
RA [125]. In that study which employed RA-FLS, IFN-
γ rapidly phosphorylated STAT-1, -3 and -6 as well as
ERK 1/2 but not Akt or NF-κB p65. Interestingly, chemical
inhibition of ERK 1/2 by PD98059 failed to overcome IFN-
γ-induced suppression of TRAIL-mediated apoptosis. Fur-
thermore, IFN-γ-mediated inhibition of TRAIL-signaling
could not be accounted for by signiﬁcant changes in TRAIL-
R, procaspases-3,-8,-9, Fas-activated death domain protein
(FADD), tumor necrosis factor receptor 1-associated death
domain protein, silencer of death domain protein, FADD-
like-interleukin-1β converting enzyme (FLICE) inhibitory
protein, bcl-2, Bcl-xL or Bax activity. These results suggested
that IFN-γ probably caused apoptosis resistance in RA-FLS
in response to TRAIL by activating the JAK/STAT pathway.
Although the precise mechanism accounting for IFN-γ-
induced suppression of TRAIL-signaling beyond activation
of STAT proteins in RA-FLS remains unknown, several more
recent studies have addressed other aspects of apoptosis
resistance in continuously proliferating cancer cells induced
by INF-γ, Thus, Bonmort et al. [126] showed that DCs also
synthesize INF-γ. Further, inhibitors of the c-kit tyrosine
kinase in combination with IL-2 were shown to promote
DC-mediated cytotoxicity of these tumor cells by TRAIL-
mediated and IFN- type IIR-mediated pathways.
Epigenetic silencing of caspase-8 activity can also result
in apoptosis resistance. In that regard, H¨ acker et al.
[127] showed that inhibitors of histone deacetylase activ-
ity, including, valproic acid, suberoylanilide hydroxamic
acid/Vorinostat,andMS-275cooperatewithIFN-γ toupreg-
ulate caspase-8 in medulloblastoma cells lacking caspase-8,
andrestoreTRAIL-mediatedcytotoxicity.Infuturestudies,it
will be interesting to determine the extent to which valproic
acid, suberoylanilide hydroxamic acid or MS-275 can restore
IFN-γ suppression of TRAIL-mediated signaling in RA-FLS.
Inanotherlineofinvestigation, Audoetal.[128]recently
showed that TRAIL-induced apoptosis was inhibited in
RA-FLS by the overexpression of the cell survival regula-
tor proteins, p21, X-inhibitor of apotosis protein, MCP-
1 and receptor-interacting protein. Furthermore, caspase-
8 played a crucial role in mediating TRAIL-induced RA-
FLS proliferation. Of note, TRAIL was shown to induce
the breakdown of p21 and p27 that were both caspase-
dependent, but independent of ERK 1/2, p38 kinase and
PI3K/Akt activity. Additionally, Pundt et al. [129] showed
that FasL- and TRAIL-mediated apoptosis in RA-SF cultures
was cell-cycle dependent. Thus, future studies should take
into consideration the pleiotypic nature of TRAIL-mediated
signaling as well as perhaps targeting cell cycle-regulating
genes in order to more appropriately deﬁne interventional
strategies for employing TRAIL agonists in vivo.
Gene transfer and intra-articular administration of
TRAIL have recently been employed to test the extent
to which these strategies could modulate TRAIL-mediated
apoptosis resistance in RA. Terzioglu et al. [130] employed
adenoviral human TRAIL (i.e., Ad5hTRAIL) gene transfer in
an attempt to overcome TRAIL-induced apoptosis resistance
in primary synovial cell cultures obtained from RA patients.
They reported that TRAIL-R was permissive for TRAIL-
induced apoptosis. However, high levels of TRAIL-R4 decoy
receptor expression correlated with TRAIL resistance. Of
note, decoy receptor-2 (DcR2) a TRAIL-R and a target for
p53 siRNA[131],butonlyin combination withAd5hTRAIL,
eliminated the TRAIL-induced resistance to apoptosis in
these cells to a more signiﬁcant extent than when the cells
were transfected with Ad5hTRAIL alone. Thus, the results of
this study suggested that modulation of TRAIL-R expression
could enable RA synoviocytes to be sensitized to TRAIL-
mediated signaling. Furthermore, TRAIL gene transfer may
beausefulstrategytotestinanimalmodelsofRAtoexamine
theextenttowhichapoptosisinductioninsynoviocytesame-
liorates arthritis severity. Employing a diﬀerent experimental
strategy, Yao et al. [86] attempted to induce synovial cell
apoptosisinarabbitmodelofexperimentalarthritisinduced
by intra-articular administration of allogeneic ﬁbroblasts
that were genetically engineered to oversecrete human IL-1β.
Arthritic rabbits were then treated either by intra-articular
administration of recombinant chimeric human TRAIL
(rhTRAIL) or with saline. The TUNEL assay demonstrated
extensive synovial cell apoptosis in the rabbits treated with
rhTRAIL compared to the saline control group and a 50%
reduction in lymphocyte inﬁltration in the inﬂamed joint.
Furthermore, intra-articular administration of rhTRAIL
altered neither the proteoglycan content of articular cartilage
nor liver function. Taken together, the results of these studies
suggested that a gene transfer strategy approach, keeping
in mind the appropriate caveats needed to extend these
experimental studies to clinical use [132], or administration
of rhTRAIL might be capable of overcoming synoviocyte
apoptosis resistance in RA.
9. Inhibition of Proteasome Activity
Proteasomes are large protein complexes that reside in
both the nucleus and cytoplasm of eukaryotic cells [134].
A principal function of the 26S-proteasome is to regulate
the concentration of completed proteins within a cell as
well as to participate in the controlled degradation of
misfolded proteins that is independent of enzyme activity
within lysosomes [135]( Figure 5). In that regard, proteins
destined for degradation in the proteasome are tagged with
ubiquitin via a reaction that is catalyzed by ubiquitin ligases.10 Mediators of Inﬂammation
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Figure 5: The Proteasome Signaling Pathway. Normally produced (left) or misfolded (right) proteins that are destined for 28S proteasome-
mediated degradation are targeted for degradation either by phosphorylation (P) or after tagging with ubiquitin (Ub), via ubiquitin
ligase [133]. In this pathway, a polyubiquitin protein chain becomes bound to the 28S proteasome providing a mechanism required for
protein degradation. Nonphosphorylated or non-Ub-tagged proteins (i.e., “activated proteins”) can bypass the proteasome pathway and be
transported to the nucleus.
Apolyubiquitinchainisformedwhichbecomesboundtothe
proteasome and provides the required structural component
forinitiating proteasome-mediated degradation. Becausethe
proteasome regulates so many of the fundamental cellular
processes that may result in aberrant proteins participating
in cell cycle progression, proliferation, protein traﬃcking,
apoptosis and immune-mediated inﬂammatory processes
[135], inhibition of the proteasome pathway has become a
promising focus of research for modulating key components
of dysfunctional protein function in cancer and immune cell
signaling [136–138].
Prosurvival cell growth factors including, mutated p53,
the E3 ubiquitin ligase hrd1, the ubiquitin-like protein
sentrin, and NF-κB were found to be increased in the
pannus of RA synovial joints [139]. Thus, the increased
concentration of these molecules is likely to be responsible
for the fact that apoptosis is rarely detected in this tissue [36,
37]. Additionally, the continued uncontrolled growth of RA
pannus despite the use of potent conventional and biologic
DMARDs is likely to be responsible for the accelerated
destruction of cartilage and bone in this disorder [38].
PS-341 (bortezomib) is a newly developed protea-
some inhibitor which induced apoptosis in cancer cells by
inhibiting the activity of the Forkhead BoxM1 (FoxM1)
transcription factor [140]. In that regard, overexpression
of FoxM1 was shown to speciﬁcally override bortezomib-
induced-apoptosis, but not doxorubicin-induced cancer cell
apoptosis. More recently, bortezomib was shown to acti-
vate the mitochondrial pathway of apoptosis in activated
CD4+ T-cells which was characterized by the accumula-
tion of proapoptotic proteins, including, p53 upregulated
modulator of apoptosis (PUMA), the bcl-2 protein family
members, Noxa and Bim as well as p53 in the mitochondrial
outer membrane [141]. Bortezomib also induced apoptosis
and inhibited NF-κB-dependent cytokine production by
activated T-cells isolated from RA patients [142]. TheseMediators of Inﬂammation 11
cytokines included, TNF-α,I L - 1 β and IL-6 and IL-10.
However, the eﬀect of bortezomib on regulating the ratio
of accumulated proinﬂammatory and antiinﬂammatory
cytokines via inhibition of NF-κB[ 143] in vitro will require
further study.
In addition, the extent to which bortezomib might alter
the activity of the newly described “secreted osteoclastogenic
factorofactivatedT-cells”(SOFAT),afactorrelevantinbone
destruction in RA, distinct from RANKL [144], should be
examined.
The use of putative proteasome inhibitors for regu-
lating autoimmune arthritis-related pathophysiology was
further complicated when Kwak et al. [145] recently showed
thatmg132, a selective proteasome inhibitor, (Ki = 4nM)
that inhibits IκB degradation and N-Acetyl-Leu-Leu-Nle-
CHO (ALLN), a calpain inhibitor, both enhanced ERK 1/2
and Akt activation resulting in osteoclast survival under
conditions of survival factor deprivation.
In murine CIA, bortezomib administered by intraperi-
toneal injection signiﬁcantly reduced the severity of arthritis
and stabilized joint structure architecture while also sup-
pressing the production of several biomarkers of immune-
mediated inﬂammation, including, TNF-α,I L - 1 β, and IL-6,
COX-2, and inducible nitric oxide synthase (iNOS) as well
as inhibiting MMP-3 synthesis [87]. No blood cell, liver or
kidney toxicity from was reported in the CIA mice treated
with bortezomib. These results suggested that proteasome
inhibition is worthy of additional study to determine the
extent to which it may become a useful adjunctive strategy
for regulating immune-mediated inﬂammatory arthritis.
10. Conclusions
In vitro cultures of immune cells and synovial ﬁbroblasts
from nonarthritic and RA patients as well as well-validated
animalmodelsofinﬂammatoryarthritishavebeenemployed
to test novel experimental strategies for attenuating proin-
ﬂammatory cytokine production, MMP biosynthesis, T-
cell and B-cell activity and inducing apoptosis as well
assessing some compounds for their capacity to dampen
the severity of clinical measures of arthritis. The discovery
of promising speciﬁc targets for intervention in the inﬂam-
matory arthritis process have included, S1P, IL-7R, Syk,
Raf/MEK/ERK 1/2, MK5/PRAK, miRNA, PI3K/PTEN/Akt,
NF-κB, TRAIL/TRAIL-R and the 28S proteasome. Altering
the biological activity of several of these targets has shown
eﬃcacy for reducing inﬂammation-related pathways espe-
cially when employed in animal models of inﬂammatory
arthritis (Table 1). The results of these studies make it highly
likely that the discovery of some of these novel targets will
eventually make their way into arthritis clinical trials.
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